Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women

HIV Medicine

Volumn 7, Issue 5, 2006, Pages 338-344

  Marazzi, M C ^a   Germano, P ^b   Liotta, Giuseppe ^c   Guidotti, G ^d   Loureiro, S ^e   da Cruz Gomes, A ^f   Valls Blazquez, M C ^e   Narciso, P ^g   Perno, C F ^c   Mancinelli, S ^c   Palombi, L ^c  

^a LUMSA UNIVERSITY   (Italy)

^b DREAM Programme ^*  (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e Dream Program Maputo   (Mozambique)

^f Catholic University of Beira   (Mozambique)

^g NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Hepatotoxicity; HIV mother to child transmission; Nevirapine containing regimen; Public health; Resource limited settings

Indexed keywords

AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; IRON; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; VIRUS RNA; ZIDOVUDINE;

AFRICA; ANEMIA; ARTICLE; ARTIFICIAL MILK; CD4+ T LYMPHOCYTE; CLINICAL PROTOCOL; COHORT ANALYSIS; DEATH; DELIVERY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; GESTATION PERIOD; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NAUSEA; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEVENS JOHNSON SYNDROME; VERTICAL TRANSMISSION; VIRUS LOAD;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MOZAMBIQUE; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 33744498986     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2006.00386.x     Document Type: Article

References (21)

1. De Maat MM, ter Heine R, van Gorp EC, Mulder JW, Mairuhu AT, Beijnen JH. Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. AIDS 2003; 17: 2253-2256.
2. Martinez E, Blanco JL, Arnaiz JA et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15: 1261-1268.
3. De Maat MM, ter Heine R, Mulder JW et al. Incidence and risk factors for nevirapine-associated rash. Eur J Clin Pharmacol 2003; 59: 457-462.
4. Ena J, Amador C, Benito C, Fenoli V, Pasquau F. Risk and determinants of developing severe liver toxicity during therapy with nevirapine- and efavirenz-containing regimens in HIV-infected patients. Int J STD AIDS 2003; 14: 776-781.
5. Martin A, Cameron P, Nolan D et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*01 and higher CD4+T cell counts. XV. International AIDS Conference. Bangkok, Thailand, July 2004 [Abstract LbOrB13].
6. Hitti J, Frenkel L, Stek A et al. Maternal toxicity with continuous nevirapine in pregnancy: Results from PACTG 1022. J Acquir Immune Defic Syndr 2004; 36: 772-776.
7. Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of non-nucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004; 38 (Suppl. 2): S80-S89.
8. Community of Sant'Egidio. DREAM. Treating AIDS in Africa. Milan, Italy: Leonardo International, 2003.
9. Marazzi MC, Palombi L, Emberti Gialloreti L et al. DREAM Project early results. Ig Sanita Pubbl 2002; 58: 431-440.
10. Palombi L, Narciso P, Perno CF et al. One year of HAART in Mozambique: survival, virological and immunological results of DREAM project in adults and children. Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 148].
11. Palombi L, Germano P, Mancinelli S et al. DREAM results from Mozambique. Predictors of mortality in a HAART treated adult cohort. XV. International AIDS Conference. Bangkok, Thailand, July 2004 [Abstract ThPeB7155].
12. World Health Organization. Scaling Up Antiretroviral Therapy in Resource-Limited Settings. Treatment Guidelines for a Public Health Approach. Geneva, Switzerland: WHO, 2003.
13. AIDS Clinical Trial Group. Table of Grading Severity of Adult Adverse Experience. http://www.aactg.org/textmenu//science_sciguidelines.asp, 1992.
14. Anonymous. United Nations Development Programme. Rapporto su lo Sviluppo Umano, Chapter 14. Le Azioni contro la Povertà. Trento, Italy, Rosenberg & Sellier, 2003.
15. World Health Organization. Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV-Infection in Infants: Guideline on Care, Treatment and Support for Women Living with HIV/AIDS and Their Children in Resource-Constrained Settings. Geneva, Switzerland: WHO, 2004.
16. Cooper ER, Charurat M, Mofenson L et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29: 484-494.
17. Mofenson LM, Lambert JS, Stiehm ER et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999; 341: 385-393.
18. Garcia PM, Kalish LA, Pitt J et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999; 341: 394-402.
19. Stern JO, Robinson PA, Love J, Lanes A, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34: S21-S33.
20. Sanne I, Mommeja-Marin H, Hinkle J et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191: 825-829.
21. Liotta G, Palombi L, Riccardi F et al. HIV infection in northern Mozambique. S Afr Med J 2002; 92: 12.